[fusion_builder_container type=»flex» hundred_percent=»no» equal_height_columns=»no» menu_anchor=»» hide_on_mobile=»small-visibility,medium-visibility,large-visibility» class=»» id=»» background_color=»» background_image=»» background_position=»center center» background_repeat=»no-repeat» fade=»no» background_parallax=»none» parallax_speed=»0.3″ video_mp4=»» video_webm=»» video_ogv=»» video_url=»» video_aspect_ratio=»16:9″ video_loop=»yes» video_mute=»yes» overlay_color=»» video_preview_image=»» border_color=»» border_style=»solid» padding_top=»» padding_bottom=»» padding_left=»» padding_right=»»][fusion_builder_row][fusion_builder_column type=»1_1″ layout=»1_1″ background_position=»left top» background_color=»» border_color=»» border_style=»solid» border_position=»all» spacing=»yes» background_image=»» background_repeat=»no-repeat» padding_top=»» padding_right=»» padding_bottom=»» padding_left=»» margin_top=»0px» margin_bottom=»0px» class=»» id=»» animation_type=»» animation_speed=»0.3″ animation_direction=»left» hide_on_mobile=»small-visibility,medium-visibility,large-visibility» center_content=»no» last=»true» min_height=»» hover_type=»none» link=»» border_sizes_top=»» border_sizes_bottom=»» border_sizes_left=»» border_sizes_right=»» first=»true»][fusion_text columns=»» column_min_width=»» column_spacing=»» rule_style=»» rule_size=»» rule_color=»» hue=»» saturation=»» lightness=»» alpha=»» content_alignment_medium=»» content_alignment_small=»» content_alignment=»» hide_on_mobile=»small-visibility,medium-visibility,large-visibility» sticky_display=»normal,sticky» class=»» id=»» margin_top=»» margin_right=»» margin_bottom=»» margin_left=»» fusion_font_family_text_font=»» fusion_font_variant_text_font=»» font_size=»» line_height=»» letter_spacing=»» text_transform=»» text_color=»» animation_type=»» animation_direction=»left» animation_color=»» animation_speed=»0.3″ animation_delay=»0″ animation_offset=»»]ZELULA Biopharma tiene su sede en San Sebastián (País Vasco) y se dedica al desarrollo de inmunoterapias contra el cáncer dirigidas al microambiente tumoral en fase preclínica. La tecnología innovadora que utilizan tiene como objetivo liberar la capacidad del sistema inmune para atacar tumores sólidos. Las principales indicaciones que exploran para el desarrollo de esta terapia CAR-T son el Cáncer de Mama Triple Negativo (TNBC) y el Osteosarcoma (OS).[/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]